Fundraising Fox

Interius BioTherapeutics

Philadelphia, US · Founded 2019 · Delaware corporation · 9 known investors

Biotech

Founders & leadership

Interius BioTherapeutics was founded in 2019 by Philip R. Johnson, M.D..

PR
Philip R. Johnson, M.D.inFounder
DM
Dora MitchellNamed on SEC filing
LF
Lori ForrestNamed on SEC filing
LM
Leon Moulder, Jr.Named on SEC filing
BL
Benjamin LundNamed on SEC filing

Board

TK
Tomas KiselakBoard director

Investors · 9

OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Pfizer Venture Investments$5M – $20M
Agent CapitalreportedWaltham
Bain Capital Life SciencesreportedBoston
Longwood FundreportedBoston
Osage University PartnersreportedBala Cynwyd
Pfizer Venturesreported
Quan CapitalreportedShanghai
RA CapitalreportedBoston

Reported raises · per SEC filings

Form D private placements

$118.1M disclosed across 4 rounds · 2020–2024

▶$51.4MraisedJun 2024 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Leon O. MoulderDirector
  • Tomas KiselakDirector
  • Bihua ChenDirector
  • Leon Moulder, Jr.Director
  • Dora MitchellExecutive Officer
  • Philip R. Johnson, M.D.Executive Officer, Director
Offering amount
$82.5M
Amount sold
$51.4M
First sale
May 2024
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$21.5MraisedOct 2023 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tomas KiselakDirector
  • Benjamin LundDirector
  • Leon Moulder, Jr.Director
  • Philip R. JohnsonExecutive Officer, Director
  • Dora MitchellExecutive Officer
Offering amount
$21.5M
Amount sold
$21.5M
First sale
Oct 2023
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$43.6MraisedMay 2021 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Dora MitchellExecutive Officer
  • Tomas KiselakDirector
  • Lori ForrestExecutive Officer
  • Leon Moulder, Jr.Director
  • Benjamin LundDirector
  • Philip R. Johnson, M.D.Executive Officer, Director
Offering amount
$76.3M
Amount sold
$43.6M
First sale
May 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.6MraisedMar 2020 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Saar GillExecutive Officer
  • Bruce PeacockExecutive Officer, Director
  • Leon O. Moulder, Jr.Director
Offering amount
$3.1M
Amount sold
$1.6M
First sale
Mar 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Penn Spinout Interius BioTherapeutics Raises Additional $67M and doses first patient - Penn Center for Innovationpci.upenn.edu · Nov 2024Penn spintout Interius BioTherapeutics raises $67M - Philadelphia Business Journalbizjournals.com · Aug 2024Penn spinout Interius Biotherapeutics raises another $21.5M - Penn Center for Innovationpci.upenn.edu · Oct 2023Interius BioTherapeutics Raises $76M in Series A Financing - FinSMEsfinsmes.com · May 2021Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platformprnewswire.com · May 2021

Frequently asked questions

Who founded Interius BioTherapeutics?
Interius BioTherapeutics was founded by Philip R. Johnson, M.D. in 2019.
Who are Interius BioTherapeutics's investors?
Interius BioTherapeutics's investors include OUP (Osage University Partners), Pfizer Venture Investments, Agent Capital, Bain Capital Life Sciences, Longwood Fund, Osage University Partners, Pfizer Ventures, Quan Capital and 1 more.
How much funding has Interius BioTherapeutics raised?
Interius BioTherapeutics has disclosed $118.1M raised across 4 rounds.
Where is Interius BioTherapeutics headquartered?
Interius BioTherapeutics is headquartered in Philadelphia, US.